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Introduction and Hypothesis. The role of inflammation is widely recognized in the pathogenesis of coronary artery disease. Research
on animal models had shown the potential benefits of targeting specific inflammatory pathways. However, studies on human
subjects are limited with small number of patients and no head-to-head comparisons. Methods. We conducted a network meta-
analysis of randomized controlled trials that studied the effects of anti-inflammatory medications on cardiovascular outcomes of
coronary artery disease patients. We searched the electronic database until March 2020 for relevant studies. Results. Nineteen
trials examining the efficacy of eight anti-inflammatory medications (pexelizumab, anakinra, colchicine, darapladib, varespladib,
canakinumab, inclacumab, and losmapimod) were selected for analysis. Overall, there is no statistically significant difference in
all-cause mortality, cardiovascular mortality, revascularization, and major cardio and cerebrovascular events (MACCE) with the
use of anti-inflammatory drugs. However, we found the use of colchicine significantly reduces the odds of developing stroke by
approximately 75% (OR 0.26, CI 0.10-0.63). Colchicine use was also associated with a lower risk of revascularization and
MACCE compared to the other agents. Our subgroup analyses comparing the timing of medication initiation (within 7 days vs.
>7 days) and clinical presentation (ACS vs. non-ACS) revealed a significant reduction in the risk of recurrent MI in the group
that received medication after seven days (OR 0.92, CI 0.86-0.99) and the non-ACS group (OR 0.88, CI 0.80-0.98). Conclusion.
Although many anti-inflammatory medications have failed to reduce adverse cardiovascular outcomes in the CAD population,
selected medications show promise among subgroups of patients without ACS or after the first week following an acute
ischemic event. Future studies examining the proper timing and targetable anti-inflammatory pathways are warranted.
1. Introduction
Each year, roughly 1.1 million patients are hospitalized with
an acute coronary syndrome (ACS) such as an acute myocar-
dial infarction (AMI) event in the United States [1]. Despite
the use of optimal guideline, directed medical therapies and
secondary prevention, recurrent ischemic coronary events,
and mortality remain high among patients with coronary
artery disease, with an annual rate of 4 to 5% after their initial
ischemic event. Accordingly, ischemic heart disease remains
the leading cause of heart failure and mortality in the western
world. Over the past 2 decades, there has been an increasing
interest in discovering therapeutic agents for reducing resid-
ual risk among patients with acute coronary syndromes
(ACS), including ST segment elevation myocardial infarction
(STEMI), non-ST segment myocardial infarction (NSTEMI),
and unstable angina [2, 3].
Decades of animal and human research have confirmed
the critical role that inflammation plays in the development
and progress of atherosclerosis. Innate immune cells such
as neutrophils and proinflammatory monocytes play a criti-
cal role in the body’s response to sterile tissue injury such
as after myocardial infarction [4]. While the immune
response is necessary for clearing dead cells and preparing
the myocardium for healing, exacerbated inflammation, as
often seen in mammals, can lead to detrimental effects.
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Studies have shown strong correlation between elevated neu-
trophil and monocyte count and infarction expansion as well
as poor clinical outcomes after AMI [5–8]. Furthermore,
attempts at modulating the immune response after AMI have
resulted in attenuated myocardial damage, reduced athero-
sclerosis burden, and enhanced survival [9–11]. This
increased interest in targeting inflammation using clinically
relevant therapies.
Modulating the inflammatory response post-AMI is an
elusive target as studies have shown that complete systemic
suppression of inflammation is rather harmful [12]. Delayed
healing and ventricular aneurysms were reported with gluco-
corticosteroids [13]. Similarly, nonsteroidal anti-
inflammatory drug use in coronary artery disease (CAD)
patients is associated with higher mortality and recurrent
AMI [14]. Additionally, studies aimed at depleting inflam-
matory cells failed to demonstrate benefit [15]. On the other
hand, selective targeting of inflammatory mediators such as
IL-1β using selective monoclonal antibodies demonstrated
success in clinical studies, albeit with high cost and modest
benefit [16–18]. Therefore, strategies aimed at modulating
the inflammatory response rather than its suppression pro-
vide therapeutic promise. However, studies using selective
targets of the inflammatory pathways in CAD patients
remain small and underpowered to reach conclusions. Fur-
thermore, with multiple new targeted anti-inflammatory
agents (referred to as anti-inflammatory drugs throughout
the manuscript), agents being studies in the field, there are
no head-to-head comparisons between and conducting such
a comparison using the randomized design will be prohibi-
tively expensive. Studies on human subjects were limited to
a small study sample and no head-to-head comparisons
[19]. In this meta-analysis, we seek to perform a cumulative
analysis of the efficacy of new anti-inflammatory drugs to
reduce clinical events among CAD patients. We also per-
formed a network meta-analysis to investigate the efficacy
and safety between these agents.
2. Materials and Methods
We conducted this protocol-driven systematic review and
meta-analysis according to the Preferred Reported Items for
Systematic Reviews and Meta-Analyses (PRISMA) [20]. We
systematically searched PubMed, Cochrane, and Scopus for
relevant studies through March 2020. The search formula
for each database is provided in detail in the online supple-
mentary appendix (available here). We also screened the ref-
erences of relevant meta-analysis and systematic reviews for
eligible studies. The abstracts of the American Heart Associ-
ation, American College of Cardiology, and European Soci-
ety of Cardiology were screened over the last 2 years for
eligible studies.
We included randomized controlled trials (RCTs) that
studied the effects of the following anti-inflammatory medi-
cations on cardiovascular outcomes of patients with coronary
artery disease: pexelizumab, colchicine, darapladib, varespla-
dib, anakinra, canakinumab, inclacumab, and losmapimod.
Our primary cardiovascular outcomes of interest were all-
cause death, cardiovascular death, recurrent myocardial
infarction, stroke, revascularization, and major adverse car-
diac and cerebrovascular events (MACCE), defined as a com-
posite of death/cardiovascular death, myocardial infarction,
and stroke. In studies that did not report this definition of
MACCE, we accepted the closest composite to our MACCE
definition. In studies that use multiple dosages of a medica-
tion, we use the highest dose except when data is only avail-
able for a lower dose across multiple studies of the same
medication. In studies that reported clinical outcomes at
multiple follow-up lengths, we included the data from the
longest available follow-up duration. We excluded studies
that did not have the cardiovascular outcomes of interest or
enrolled patients with significant medical comorbidities that
may affect the outcomes (e.g., cancer patients who receive
chemotherapy).
Two reviewers (E.S and I.W) independently screened and
evaluated the eligibility of the studies using the aforemen-
tioned criteria. Studies were initially screened by title and
abstract. After initial screening, the full text of the identified
studies was reviewed thoroughly to determine their eligibil-
ity. Baseline characteristics and clinical outcomes of interest
were extracted using a standardized data extraction form.
Disagreements were resolved through discussions, and the
opinion of a third investigator (M.A.) was requested if neces-
sary. Quality assessment of the studies was performed using
the Cochrane Collaboration’s risk of bias tool [21].
2.1. Statistical Analyses. The prespecified outcomes of our
analyses were all-cause mortality, cardiac mortality, recur-
rent myocardial infarction, stroke, revascularization, and
major adverse cardiac and cerebrovascular events (MACCE).
Summary estimates were calculated as odds ratios (OR) with
95% confidence intervals (CI) using the random-effects
model based on DerSimonian and Laird’s meta-analytic sta-
tistical method [22]. Considering the heterogeneity of the
included trials and its potential influence on treatment
effects, we prespecified the use of random-effects model to
assess effect sizes. The I2 index was used to summarize the
proportion of total variability in the estimate. The I2 statistic
is derived from the Q statistic and describes the percentage of
total variation across studies attributed to heterogeneity;
values of 25%, 50%, and 75% correspond to low, moderate,
and high heterogeneity, respectively [23, 24]. We performed
subgroup analyses according to (a) type of enrolled popula-
tion in studies (stable coronary heart disease and CABG vs.
ACS) and (b) the duration between symptom onset/index
event and study medication administration. We used visual
inspection of funnel plots to assess for publication bias. The
statistical level of significance was 2-tailed P < 0:05. Analyses
were performed using Review Manager version 5.3 (Revman;
The Cochrane Collaboration, Oxford, UK).
In the network meta-analysis, we used the Bayesian Mar-
kov chainMonte Carlo modelling using the informative prior
setting. The Bayesian model was selected because of its
greater flexibility and ability to rank treatments according
to their comparative effectiveness. Informative prior was
chosen to assume consistency between heterogeneity vari-
ances and ensure a realistic heterogeneity estimation [25].
All network analyses were performed with NetMetaXL 1.6.1
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(Canadian Agency for Drugs and Technologies in Health,
Ottawa, Canada) and WinBUGS 1.4.3 (MRC Biostatistics
Unit, Cambridge, United Kingdom) [26]. A burn-in phase
of 20,000 iterations was used to achieve convergence. The
convergence was assessed using the Brooks-Gelman-Rubin
plots. NetMetaXL fits three chains for Bayesian network
meta-analysis. We evaluated heterogeneity using the
between-study heterogeneity variances per outcome, known
as τ2 (tau-squared) and its 95% CI. Inconsistency was eval-
uated by plotting the posterior mean deviation of individ-
ual data points in the inconsistency model against its
posterior mean deviation in the consistency model to iden-
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• Absence of cardiovascular outcomes of
 our interest (n = 8)
• Author’s decision that study introduces
 heterogeneity (n =1)
• Presence of comorbidities which affect the
 cardiovascular outcomes (n =1)
Studies included aer full-text review (19 trials)

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 Mediators of Inflammation
3. Results
Our literature search yielded a total of 1963 trials, as shown
in Figure 1. After title and abstract screening and full-text
review, nineteen trials including 70,620 patients met our
inclusion criteria utilizing the following medications: pexeli-
zumab (6 studies) [16, 28–32], anakinra (3 studies) [33–35],
colchicine (2 studies) [36, 37], darapladib (2 studies) [38,
39], varespladib (2 studies) [40, 41], canakinumab (1 study)
[17], inclacumab (1 study) [42], and losmapimod (2 studies)
[3, 43]. The baseline characteristics of the study population
are shown in Table 1. The median patient age ranges from
53-67 years old, 77.3% of the patient population were males,
and the follow-up duration ranged from 30 days to 3.7 years.
Overall, patients included in this meta-analysis had the
typical comorbidities of this cohort including diabetes,
hypertension, hyperlipidemia, and high prevalence of smok-
ing. Population of patients included in our meta-analysis
ranged from chronic CAD (34.8%), patients undergoing
CABG (11.7%), and ACS patients (57%). Of the total number
of 19 studies, 6 trials enrolled stable coronary artery disease
[30–32, 36, 39, 42] patients, 3 trials investigated ACS patients
with spectrum of unstable angina to STEMI [38, 40, 41], 3
trials enrolled patients with either STEMI or NSTEMI [17,
37, 43], 5 studies only included patients who presented with
STEMI [16, 28, 29, 33, 34], and 2 trials enrolled only
NSTEMI patients [3, 35].
The breakdown of the trials with the corresponding
patient populations is shown in Table 2. The quality assess-
ment of the included studies is displayed in Supplemental
Table 1 of the Appendix.
3.1. Meta-Analysis Results. There was a reduction in the risk
of revascularization (OR 0.85, CI 0.73-1.00; P = 0:04) with
the use of anti-inflammatory drugs compared to standard
of care alone (Figure 2). However, there was no statistically
significant difference in cardiovascular mortality (OR 0.93,
CI 0.84-1.02; P = 0:13), all-cause mortality (OR 0.96, CI
0.87-1.05; P = 0:38), stroke (OR 0.96, CI 0.82-1.13; P = 0:65),
recurrent myocardial infarction (OR 0.99, CI 0.89-1.10;
P = 0:82), and major adverse cardio and cerebrovascular
events (MACCE) (OR 0.95, CI 0.87-1.04; P = 0:24) with the
use of anti-inflammatory medications (Figures 3–7).
While we did not observe a significant reduction in the
incidence of stroke with the use of anti-inflammatory drugs,
we found the use of colchicine significantly reduces the stroke
odds by approximately 75% in patients with coronary artery
disease (OR 0.26, CI 0.10-0.63; P = 0:003) (Figure 5). On the
other hand, we found that the use of anakinra was associated
with an almost fourfold increase in the risk of developing
recurrent MI (OR 3.85, CI 1.04-14.28; P = 0:04) (Figure 6).
Lastly, although the PRIMO CABG trial had previously
shown that pexelizumab treatment improves MACCE in
patients undergoing CABG, our pooled analysis showed
only a trend in the reduction of MACCE with pexelizumab
compared to placebo (OR 0.93, CI 0.84-1.02; P = 0:12)
(Figure 7).
3.2. Subgroup Analysis
3.2.1. Acute vs. Subacute vs. Chronic Presentation. The results
of the subgroup analyses according to time of study medica-
tion initiation after symptom onset/index event (7 days vs. >7
days) are summarized in Table 3. Patients who were given
study medications after 7 days of index ischemic event dem-
onstrated reduced risk for developing recurrent MI and
revascularization (P value for interaction = 0:03). There was
also a trend in favor of drug initiation after 7 days from
symptom onset or index clinical event in all-cause mortality,
cardiac mortality, and MACCE.
Table 2: Patient population and clinical scenario among included studies.






NSTEMI MRC-ILA Heart Study [35] Anakinra
MI (STEMI and NSTEMI)
CANTOS [17] Canakinumab
LATITUDE TIMI 60 [43] Losmapimod
COLCOT [37] Colchicine
ACS (STEMI, NSTEMI, or UA)




PRIMO CABG 1 [32]
PexelizumabPRIMO CABG 2 [31]





∗Study with subgroup analysis of its primary end points.
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3.3. ACS vs. Non-ACS Presentation. The sensitivity analysis
based on clinical presentation (ACS vs. non-ACS) is summa-
rized in Table 3. In our study, the use of anti-inflammatory
medications was found to reduce the risk of recurrent MI
in the non-ACS population compared to the ACS population
(OR 0.88, CI 0.80-0.98; P = 0:04). There was also a trend in
favor of starting anti-inflammatory drugs in non-ACS
patients when MACCE was assessed. Meanwhile, no signifi-
cant differences in other cardiovascular outcomes (e.g., all-
cause mortality, CV death, stroke, and recurrent MI) were
noted in our analyses.
3.4. Network Meta-Analysis. Supplemental Figures 1–6 show
the forest plot comparing the relative efficacies of each
anti-inflammatory medication on all-cause mortality,
cardiovascular death, recurrent myocardial infarction,
revascularization, stroke, and MACCE. We found the use of
colchicine was significantly associated with reduced risk of
revascularization, stroke, and MACCE in comparison with
several anti-inflammatory medications in our study.
Specifically, colchicine was associated with lower risk of
revascularization events than both anakinra and darapladib
(OR 0.31, CI 0.11-0.84 and OR 0.52, CI 0.29-0.93). It was
also associated with lower risk of stroke after MI when
compared with the use of darapladib, pexelizumab,
losmapimod, canakinumab, and varespladib (OR 0.23, CI
0.07-0.57; OR 0.23, CI 0.07-0.64; OR 0.25, CI 0.07-0.85; OR
0.30, CI 0.09-0.81; and OR 0.26, CI 0.07-0.97, respectively).
Furthermore, colchicine use was also associated with lower
risk of MACCE compared to darapladib, losmapimod,
anakinra, or varespladib (OR 0.69, CI 0.44-0.98; OR 0.60,
CI 0.37-0.93; OR 0.28, CI 0.10-0.70; and OR 0.53, CI 0.32-
0.83, respectively). Visualization of the network meta-
analysis is depicted in Supplemental Figure 7.










MRC-ILA Heart Study, 2015
VCUART 1 and 2
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 0.00, df = 1 (P = 1.00); I2 = 0%
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Heterogeneity: Tau2 = 0.00; Chi2 = 0.09, df = 1 (P = 0.77); I2 = 0%






















































Events Total Events Total
Weight
M-H, Random, 95% CI
Odds Ratio
M-H, Random, 95% CI
Heterogeneity: Tau2 =0.02; Chi2 = 17.26, df = 8 (P = 0.03); I2 = 54%
Test for overall effect: Z = 2.01 (P = 0.04)
Test for subgroup differences: Chi2 = 17.17, df = 6 (P = 0.009), I2 = 65.0%
Figure 2: Forest plot for the comparative risk of revascularization with anti-inflammatory therapy versus standard of care alone. Anti-
inflammatory therapy significantly reduced the risk of revascularization (OR 0.85, CI 0.73-1.00; P < 0:05).
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3.5. Assessment of Heterogeneity. We drew funnel plots to
seek evidence of publication bias: where inconsistency was
high, the funnel plots were not interpretable; where inconsis-
tency was low, the funnel plots were inconclusive (Supple-
mental Figure 8). In the network meta-analysis, we did not
observe significant inconsistency in our analysis of the
outcomes (Supplemental Figure 9).
4. Discussion
The use of selective anti-inflammatory drugs to reduce the
incidence of cardiovascular events in high-risk patients with
CAD is debatable in the clinical community. We conducted
a systematic review and network meta-analysis to study the
effect of several anti-inflammatory medications on cardio-
vascular outcomes in coronary artery disease patients. In
our systematic review of eight anti-inflammatory medica-
tions, we observed a modest reduction in cardiovascular out-
comes when compared with placebo. However, as previously
published, the use of colchicine and canakinumab did show a
beneficial effect on reducing the risk of revascularization
post-AMI [17, 37]. Furthermore, there was a significant
reduction in the incidence of stroke in the CAD population
who received colchicine as compared with the placebo-
treated group. Colchicine use was also associated with lower
odds of MACCE compared to other selective anti-
inflammatory agents.
Our subgroup analyses based on the timing of medica-
tion initiation (<7 days vs. >7 days) and patient’s clinical pre-
sentation (ACS vs. non-ACS) demonstrated interesting and
unexpected results. Theoretically, the administration of
anti-inflammatory agents is expected to demonstrate benefit
during heightened inflammation after ACS. However, our
subgroup analyses suggest that anti-inflammatory drugs




















































































Test for overall effect: Z = 0.61 (p = 0.54)
Total (95% CI)
Total events
Heterogeneity: Chi2 = 6.73, df = 7 (P = 0.46); I2 = 0%
Test for overall effect: Z = 1.51 (p = 0.13)
Test for subgroup differences: Chi2 = 4.37, df = 5 (p = 0.50), I2 =0%















Test for overall effect: Z = 0.59 (p = 0.55)




Heterogeneity: Chi2 = 0.36, df = 1 (p = 0.55); I2 = 0%





Heterogeneity: Chi2 = 4.79, df = 1 (p = 0.03); I2 = 79%






































M-H, Random, 95% CI
Odds Ratio
M-H, Random, 95% CI
Figure 3: Forest plot of cardiac mortality. There was no significant difference between anti-inflammatory therapy and standard therapy alone
regarding cardiovascular mortality (OR 0.93, CI 0.84-1.02; P = 0:13).
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could potentially be more beneficial among patients with
non-ACS presentation and those initiated on therapy after
7 days from symptom onset. This could be explained by the
physiological importance of the nonsterile inflammatory
response early after coronary ischemia [12]. It has been dem-
onstrated in animal studies that depleting inflammatory cells
such as neutrophils and macrophages after AMI is rather det-
rimental and could result in increased mortality and exacer-
bation of heart failure. To our knowledge, there has not
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Heterogeneity: Tau2 = 0.00; Chi2 = 1.94, df = 2 (p = 0.38); I2 = 0%







































PEXELIZUMAB Study Investigators, 2004
PRIMO CABG I, 2006
PRIMO CABG II, 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.03; Chi2 = 8.33, df = 5 (p = 0.14); I2 = 40%
Test for overall effect: Z = 1.23 (p = 0.22)
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0.01 0.1 1 10 100
0.96 [0.87, 1.05]Total (95% CI)
Total events
Heterogeneity: Tau2 = 0.01; Chi2 = 18.55, df = 15 (p = 0.24); I2 = 19%
Test for overall effect: Z = 0.88 (p = 0.38)
Test for subgroup differences: Chi2 = 5.38, df = 5 (p = 0.37), I2 =7.0%
Figure 4: Forest plot of all-cause mortality. No significant difference was observed in the risk of all-cause mortality between anti-
inflammatory therapy and standard therapy alone (OR 0.96, CI 0.87-1.05; P = 0:38).
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anti-inflammatory medications given at different time points
after index events. We believe future studies that compare the
timing of medication administration and its association with
cardiovascular outcomes are necessary to further explore the
underpinnings of this phenomenon.
4.1. Colchicine and Stroke Incidence. Our study finding was
consistent with a recently published meta-analysis study that
looked into the efficacy of colchicine in preventing stroke in
patients with coronary artery disease. Even though our anal-
ysis excluded two studies included in this meta-analysis, due
to the absence of cardiovascular outcomes as either primary
or secondary endpoints, a similar degree of stroke risk reduc-
tion was demonstrated (OR 0.31, 95% confidence interval:
0.13-0.71; P = 0:006) [44]. The proposed mechanisms of
action of colchicine are through its effect on neutrophil and
monocytes through inhibition of NLRP3 inflammasome
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MRC-ILA Heart Study, 2015
VCUART 1 and 2
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 0.90, df = 1 (p = 0.34); I2 = 0%




































PEXELIZUMAB Study Investigators, 2004
PRIMO CABG I, 2006
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 1.94, df = 2 (p = 0.38); I2 = 0%
Test for overall effect: Z = 0.26 (p = 0.79)
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0.01 0.1 1 10 100
467
28757 0.96 [0.82, 1.13]Total (95% CI)
Total events
Heterogeneity: Tau2 = 0.01; Chi2 = 14.34, df = 13 (p = 0.35); I2 = 9%
Test for overall effect: Z = 0.46 (p = 0.65)
Test for subgroup differences: Chi2 = 11.07, df = 7 (p = 0.14), I2 =36.8%
12.5%
23
Figure 5: Forest plot of stroke. There was no significant difference between anti-inflammatory therapy and standard therapy alone in regard
to stroke (OR 0.96, CI 0.82-1.13; P = 0:65).
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the production of IL-1 beta and IL-18 and prevents the
migration of inflammatory cells, respectively. Inhibition of
these pathways had been shown to decrease both hsCRP
levels and atherosclerotic plaque progression as well as insta-
bility on CT scan [45]. It is worth noting that the pooled clin-
ical benefit seen with the use of colchicine in our study largely
derived from the study population with acute myocardial
infarction as opposed to stable coronary disease [36, 37]. It
is possible that this finding is related to higher transcoronary
gradients of IL-1 and IL-18 seen in the ACS than the stable
CAD population [46]. Thus, inhibition of these interleukins
by colchicine might explain the reduced risk of stroke in
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MRC-ILA Heart Study, 2015
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PEXELIZUMAB Study Investigators, 2004
PRIMO CABG I, 2006
PRIMO CABG II, 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.01; Chi2 = 5.99, df = 4 (p = 0.20); I2 = 33%
Test for overall effect: Z = 0.61 (p = 0.54)
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Heterogeneity: Tau2 = 0.02; Chi2 = 25.26, df = 14 (p = 0.03); I2 = 45%
Test for overall effect: Z = 0.23 (p = 0.82)
Test for subgroup differences: Chi2 = 8.15, df = 7 (p = 0.32), I2 =14.1%
Figure 6: Forest plot of recurrent myocardial infarction. No significant difference was observed between anti-inflammatory therapy and
standard therapy in terms of recurrent myocardial infarction (OR 0.99, CI 0.89-1.10; P = 0:82).
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4.2. Anakinra and Recurrent MI. Our findings are consistent
with a recent meta-analysis that studied the effect of IL-1
blockage on cardiovascular risk. The authors found an over-
all increased risk of recurrent MI with anakinra after pooling
data from a total of five anakinra trials [47]. Although we
only included three of the five trials based on our prespecified
inclusion criteria (we excluded one study that included only
the heart failure population and another study that did not
have cardiovascular outcome as either primary or secondary
end points) in our analysis, we found similar risk estimates
with a wide confidence interval. This finding is in contrast
with the CANTOS trial where the use of another IL-1 block-
ade medication, canakinumab, had resulted in decreased risk
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Figure 7: Forest plot of MACCE. There was no significant difference between anti-inflammatory therapy and standard therapy alone
regarding MACCE (OR 0.95, CI 0.87-1.04; P = 0:24).
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Although no definite explanation exists yet as per our knowl-
edge, we believe it is possible that the timing and duration of
drug administration may play a crucial role in determining
response to medication.
4.3. Pexelizumab and Cardiovascular Outcomes. Our finding
was consistent with a previous meta-analysis that included
seven pexelizumab studies. They also did not find any signif-
icant improvements in major adverse cardiovascular out-
comes and its components with the use of pexelizumab
compared with placebo. However, they did find a 26%
decreased risk of death in the CABG subpopulation (OR
0.74 [0.58–0.94]; P = 0:01). It is hypothesized that the benefit
seen in primarily CABG population may be related to the
presence of intact microvascular system, salvageable myocar-
dium, ability of the medication to penetrate the tissues, differ-
ences in the inflammatory pathway involved, and degree of
complement system activation in this population as com-
pared to the ACS population. Upstream delivery of pexelizu-
mab in the STEMI population may not be effective as
irreversible damage to the vascular system and myocardium
prevents the penetration of medication to the site of inflam-
mation yielding the drug less effective [48].
5. Study Limitations
There were some limitations to this study. First, although we
included all patients with coronary artery disease, they range
in severity of clinical presentation from stable coronary heart
disease to acute coronary syndrome requiring revasculariza-
tion procedure (PCI or CABG). This heterogeneity could
explain some of our findings and we aimed to address them
by conducting extensive subgroup analyses. Second, there is
variability in the length of follow-up among trials from 30
days to 3.7 years. Third, the three anakinra trials that were
included in our analysis are small studies with less than 200
patients. Although we see a potential harm with the use of
anakinra (increased risk of recurrent MI), the potential bias
with the small study sample must not be overlooked. Further
larger anakinra studies will be required to explore this inter-
esting association. Fourth, the trials of two medications in
our study (pexelizumab and varespladib) did not exactly have
the same intervention protocol. Two out of the six pexelizu-
mab trials (COMMA and COMPLY) were given an infusion
of only 20 hours as opposed to the 24-hour duration studies
in the rest of the studies. Additionally, although both vares-
pladib trials (FRANCIS and VISTA-16 trials) utilized the
same dose of varespladib, the duration of treatment and the
statin dose are different (24 vs. 16 weeks and 80mg vs. at least
20mg, respectively).
Despite these limitations, our analysis has several
strengths. To our knowledge, this is the first study to assess
the cumulative efficacy of eight different anti-inflammatory
medications and compare their individual efficacy on cardio-
vascular outcomes of patients with coronary artery disease.
Second, our study was also the first to analyze the efficacy
Table 3: Subgroup analyses.
Clinical presentation








All-cause mortality 0.87 (0.71-1.07) 0.89 (0.59-1.34) 0.92 2.47 (0.47-13.08) 0.22
Stroke 0.97 (0.60-1.55) 1.06 (0.69-1.62) 0.78 2.90 (0.12-72.20) 0.51
Recurrent MI 0.94 (0.81-1.09) 1.20 (0.89-1.62) 0.15 4.309 (0.84-19.84) 0.06
Revascularization 0.93 (0.82-1.09) — — 1.060 (0.65-3.95) 0.78
MACCE 0.81 (0.65-1.01) 1.02 (0.91-1.13) 0.07 1.29 (0.94-1.77) 0.02
Timing after acute event
≤7 days >7 days
All-cause mortality 1.08 (0.82-1.41) 0.94 (0.87-1.02) 0.33
Cardiac mortality 1.12 (0.70-1.79) 0.92 (0.83-1.02) 0.42
Stroke 1.03 (0.70-1.50) 0.90 (0.70-1.16) 0.56
Recurrent MI 1.34 (0.97-1.86) 0.92 (0.86-0.99)∗ 0.03
Revascularization 1.54 (0.70-3.36) 0.83 (0.71-0.98)∗ 0.03
MACCE 1.08 (0.93-1.26) 0.91 (0.82-1.00) 0.06
Clinical presentation
ACS Non-ACS
All-cause mortality 0.99 (0.88-1.11) 0.87 (0.71-1.07) 0.28
Cardiac mortality 0.92 (0.81-1.04) 0.94 (0.80-1.10) 0.84
Stroke 0.93 (0.74-1.16) 0.97 (0.60-1.55) 0.88
Recurrent MI 1.08 (0.91-1.27) 0.88 (0.80-0.98)∗ 0.04
Revascularization 0.83 (0.65-1.07) 0.93 (0.82-1.05) 0.42
MACCE 0.99 (0.91-1.08) 0.83 (0.68-1.01) 0.11
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of anti-inflammatory medication based on timing of drug
administration and patient’s clinical presentation. Third,
our outcomes of interest (e.g., death, CV death, and MI) are
largely objective findings and most of the trials included in
our study have independent event adjudicators, thus mini-
mizing the risk of measurement bias.
6. Conclusion
When applied to a largely unselected patient population with
coronary artery disease, anti-inflammatory medications
failed to reduce adverse cardiovascular outcomes. However,
selected agents show promise among subgroups of patients
without ACS or after the first week following an acute ische-
mic event. Future studies examining the proper timing and
targetable inflammatory pathways are warranted.
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Supplemental Figure 1: forest plot for network meta-
analysis comparing the relative efficacy of each anti-
inflammatory medication on all-cause death. Use of pexeli-
zumab is associated with lower risk of all-cause mortality in
comparison with veraspladib (OR 0.62, CI 0.37–0.99). Sup-
plemental Figure 2: forest plot for network meta-analysis
comparing the relative efficacies of each anti-inflammatory
medication on cardiovascular death. Supplemental Figure 3:
forest plot for network meta-analysis of myocardial infarc-
tion. Uses of canakinumab, colchicine, darapladib, and pexe-
lizumab were associated with lower risk of recurrent
myocardial infarction in comparison with anakinra (OR
0.20, CI 0.04–0.79; OR 0.21, CI 0.04–0.83; OR 0.22, CI
0.04–0.81; and OR 0.22, CI 0.05–0.82, respectively). Supple-
mental Figure 4: forest plot for network meta-analysis of
revascularization. Use of colchicine significantly reduced
the risk of revascularization in comparison to both anakinra
and darapladib (OR 0.31, CI 0.11–0.84 and OR 0.52, CI 0.29–
0.93, respectively). Supplemental Figure 5: forest plot for net-
work meta-analysis of stroke. Use of colchicine was associ-
ated with significant reduced risk of stroke events after
myocardial infarction in comparison to several anti-
inflammatory medications including: darapladib (OR 0.23,
CI 0.07-0.57), pexelizumab (OR 0.23, CI 0.07-0.64), losmapi-
mod (OR 0.25, CI 0.07-0.85), canakinumab (OR 0.30, CI
0.09-0.81), and veraspladib (OR 0.26, CI 0.07-0.97). Supple-
mental Figure 6: forest plot for network meta-analysis com-
paring the relative efficacy of each anti-inflammatory
medication on major adverse cardiac and cerebrovascular
events (MAACE). Colchicine use was associated with signif-
icantly lower risk of MACCE when compared to darapladib
(OR 0.69, CI 0.44-0.98), losmapimod (OR 0.60, CI 0.37-
0.93), anakinra (OR 0.28 CI 0.10–0.70), and varespladib
(OR 0.53, CI 0.32-0.83). Both canakinumab and pexelizumab
were associated with reduced risk of MACCE (OR 0.37, CI
0.13–0.95 and OR 0.39, CI 0.14–0.96, respectively). Supple-
mental Figure 7: network plot of treatments included in this
network meta-analysis. Circles represent the intervention as
a node in the network, lines represent direct comparisons
using randomized clinical trials (RCTs), and the thickness
of lines corresponds to the number of (RCTs) included in
each comparison. Supplemental Figure 8: funnel plots of
odds ratios and standard errors to assess the publication bias
of all-cause mortality, cardiac mortality, revascularization,
stroke, recurrent myocardial infarction, and major adverse
cardiac and cerebrovascular events (MACCE). Supplemental
Figure 9: consistency plot for all-cause mortality, cardiac
mortality, revascularization, stroke, recurrent myocardial
infarction, and major adverse cardiac and cerebrovascular
events (MACCE). (Supplementary Materials)
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